Clinical Trial Update: An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 study evaluating chemoradiotherapy with AT-101 in locally advanced esophageal or gastroesophageal junction cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• AT-101 (gossypol acetic acid)

Snippet

Sponsor: Ascenta Therapeutics | Conditions: Locally Advanced Esophageal or GE Junction Cancer | Phase 1, Phase 2 | Status: TERMINATED